聶祥碧

[摘要] 目的 評(píng)價(jià)厄貝沙坦聯(lián)合氨氯地平治療老年高血壓患者效果。方法 研究對(duì)象為方便選取2015年2月—2018年2月老年高血壓患者例數(shù)200例，采用每日患者掛號(hào)的自然序列，單號(hào)為觀察組，雙號(hào)為對(duì)照組，分別實(shí)施厄貝沙坦聯(lián)合氨氯地平治療以及常規(guī)治療，將兩組患者的血壓水平、治療效果、腎小管功能指標(biāo)以及尿微量蛋白指標(biāo)進(jìn)行對(duì)比。結(jié)果 治療后，觀察組收縮壓（125.52±1.34）mmHg、舒張壓（70.64±1.32）mmHg均低于對(duì)照組（t=54.458 3、57.286 2，P<0.05）;觀察組NAG（11.32±1.02）mg/L、Kim-1（469.32±1.54）ng/L，較對(duì)照組指標(biāo)更有優(yōu)勢(shì)（t=34.328 8、288.895 5，P<0.05）;觀察組治療總有效率95.00%高于對(duì)照組74.00%（χ2=16.835 3，P<0.05）;治療后，觀察組老年高血壓患者mAlb（14.09±5.61）mg/L、RBP（0.21±0.06）mg/L低于對(duì)照組（t=7.730 2，16.641 0，P<0.05）。結(jié)論 厄貝沙坦聯(lián)合氨氯地平治療老年高血壓患者的效果十分顯著，且安全性較高，對(duì)腎臟具有保護(hù)作用。

[關(guān)鍵詞] 厄貝沙坦;氨氯地平;老年高血壓;效果評(píng)價(jià)

[中圖分類號(hào)] R5? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1674-0742（2019）09（a）-0097-03

[Abstract] Objective Convenient selected to evaluate the effect of irbesartan combined with amlodipine in the treatment of elderly hypertensive patients. Methods A total of 200 elderly patients with hypertension from February 2015 to February 2018 were enrolled. The natural sequence of daily patient registration was used. The single number was the observation group and the double number was the control group. The irbesartan combined with amlodipine and conventional treatment were performed. Blood pressure levels， treatment effects， renal tubular function indicators， and urine microprotein indicators were compared between the two groups. Results After treatment the systolic blood pressure （125.52±1.34） mmHg and diastolic blood pressure （70.64±1.32） mmHg in the observation group were lower than those in the control group （t=54.458 3， 57.286 2，P<0.05）; observation group NAG （11.32±1.02） mg/L， Kim-1 （469.32±1.54） ng/L， which was superior to the control group （t=34.328 8，288.895 5，P<0.05）; the total effective rate of the observation group was 95.00% higher than that of the control group 74.00% （χ2=16.835 3，P<0.05）; after treatment， mAlb （14.09±5.61） mg/L and RBP （0.21±0.06） mg/L in elderly hypertensive patients in the observation group were lower than the control group（t=7.730 2，16.604 1，P<0.05）. Conclusion The efficacy of irbesartan combined with amlodipine in the treatment of elderly hypertensive patients is very significant， and it is safe and has a protective effect on the kidney.

[Key words] Irbesartan; Amlodipine; Elderly hypertension; Effect evaluation

隨著社會(huì)人口老年化，老年高血壓發(fā)病率隨年齡增長(zhǎng)而增高，老年人易受到器官功能儲(chǔ)備能力下降、多病共存、服藥種類較多等多種因素的影響，故此，在選擇藥物方面，應(yīng)以不良反應(yīng)小，藥物間相互不良反應(yīng)小的藥物、方便、依從性好的藥物為主，能夠提高治療安全性，避免不良事件的發(fā)生[1-2]。因此，該院將收取時(shí)間在2015年2月—2018年2月200例老年高血壓患者作為研究對(duì)象，分別實(shí)施不同治療，探討治療效果，現(xiàn)報(bào)道如下。

1? 資料與方法